Individuals who take liraglutide or semaglutide for weight loss reduce their alcohol consumption by almost two-thirds in four months, new research presented at the European Congress on Obesity (ECO 2025) has found.
Novo Nordisk, the maker of Ozempic, just released its first-quarter results, and they’re eye-popping: $4.4 billion in revenue, up 14% from the same period last year. That surge has sent the company’s stock price soaring. But the more interesting story is why. The answer is simple: demand for obesity treatments is up 67%. The Ozempic … Read more
For years, weight loss has been sold as a simple math problem: eat less, move more, and the pounds will melt away. But if that were true, we wouldn’t have an obesity epidemic affecting over 40 percent of adults in the U.S. Now, a new class of medications—GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and … Read more
The popularity of glucagon-like peptide-1 (GLP-1) receptor agonists continues, with use of tirzepatide and semaglutide surpassing that of traditional weight-lowering medications.
Ozempic has gained fame as a powerful drug for controlling blood sugar and curbing cravings as a weight loss drug. But what if the body had its own built-in version? New research suggests it just might. Scientists have identified a gut microbe that could serve as a natural Ozempic, offering a way to manage diabetes … Read more
March 14, 2025 Hunter Gibble T, Chinthammit C, Ward JM, Cappell K, Sedgley R, Bonafede M, Liao B, Hankosky ER. Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database. Diabetes Obes Metab. 2025 Jun;27(6):3185-3194. doi: 10.1111/dom.16330. Epub 2025 Mar 14. PMID: 40084533; PMCID: PMC12046461. This source describes … Read more
Millions of Americans fighting obesity faced a setback last month when the Trump administration declined to allow Medicare and Medicaid to cover popular weight loss drugs like Wegovy and Zepbound. The Centers for Medicare & Medicaid Services (CMS) last month rejected a proposal from the Biden administration that would have required Medicare and Medicaid to … Read more
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand in the U.S. Karsten Munk Knudsen, Novo Nordisk’s chief financial officer, told Fortune the company is well-placed to handle the geopolitical upheaval that rocked global business in March and April. The dust has … Read more
Barbara Pfeffer Billauer, ACSH We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a growing swarm of lawsuits threatens to…
